Doseology Unveils New Leadership and Completes Shares-for-Debt Settlement

Doseology's Fresh Leadership and Innovative Direction

Doseology Sciences Inc., a company making strides in the consumer product innovation sector, has announced significant changes in its leadership team amid a strategic pivot towards growing its unique oral pouch and functional stimulant technologies. With a renewed focus on innovation and operational excellence, Doseology aims to capitalize on the expanding market opportunities in the oral stimulant category.

In a recent press release dated September 30, 2026, Doseology revealed the appointment of Kareem Baalbaki as the interim CEO, interim CFO, and a director of the company. Baalbaki, who hails from a background steeped in operations and supply chain management, has garnered over a decade of experience helping high-growth businesses scale efficiently. Notably, his prior role as Chief Supply Chain Officer at Revive Superfoods positions him as a valuable asset in guiding Doseology’s operational strategies. Under his watch, Revive Superfoods saw its revenue soar from approximately $10 million to an impressive $150 million annually. Kareem’s transition to Doseology is a promising move, suggesting a proactive approach to navigating the complexities of the consumer packaged goods (CPG) landscape.

Joining Baalbaki is Jeremy Wright, a seasoned financial strategist with depth in public company finance. Currently the Chief Financial Officer at Avant Brands Inc., Wright’s experience includes being the founding CFO of GTEC Holdings, where he played a pivotal role in securing over $45 million in capital and shaping the strategic direction that led to a successful TSX uplisting. His appointment at Doseology reflects the company’s commitment to strong financial governance and operational efficacy as it embarks on its next growth phase. Jeremy’s extensive background in capital markets and regulatory frameworks will be critical as Doseology positions itself within North America’s competitive CPG landscape.

The company also announced the resignation of Chris Jackson as CEO and Chris Cherry as CFO, marking a significant leadership reshuffle aimed at bringing fresh perspectives and skills to the forefront. Such changes typically accompany a phase of transformation, and for Doseology, this shift signals a robust commitment to innovate more effectively within its sector.

In addition to leadership changes, Doseology also disclosed a successful settlement of shares for debt. The agreement involved issuing 75,268 common shares at a deemed price of $0.18 per share to settle approximately $13,548.39 in accrued consulting compensation. This strategic financial maneuver is designed to streamline operations and alleviate some financial burdens while optimizing shareholder equity.

Headquartered in Kelowna, BC, Doseology specializes in pouch-based oral stimulant products, carving a niche in a booming sector that increasingly values convenience and innovation. The oral pouch product category has been gaining traction, as consumers search for alternatives to traditional nicotine and stimulant delivery methods. By focusing on smokeless and vapor-free options, Doseology positions itself as a leading force in modern consumer product innovation, enhancing both user experience and consumer safety.

As Doseology shifts into this new chapter, industry observers remain eager to see how these leadership changes and strategic initiatives will translate into market performance. The company's emphasis on operational excellence and strategic governance under Baalbaki and Wright, combined with its innovative product offerings, sets the stage for significant developments ahead. The rapid global growth of oral pouch products indicates a substantive demand that Doseology is well-positioned to meet.

For more updates on Doseology Sciences Inc and its innovative oral pouch products, visit their official website at doseology.com.